The CHLOE Study: Shaping the Future of HER2+ MBC Research
Join us for this GRASP Huddle, discussing the CHLOE Registry at Yale Cancer Center. The CHLOE Registry focuses on patients diagnosed with de novo HER2+ metastatic breast cancer—meaning the cancer had already spread at the time of diagnosis. The study specifically looks at patients with oligometastatic disease, or limited spread to just one or two distant sites, that have been newly diagnosed within the past year.
Unlike interventional studies, CHLOE is observational—meaning it does not change or guide treatment decisions. Participation is purely for data collection and learning, and all treatment decisions remain between the patient and their oncologist.
During this Huddle, Dr. Mariya Rozenblit will discuss:
– Who qualifies to participate (including international patients)
– How to join the study
– Why this kind of research matters for the future of patient care
Your voice matters! Whether you’re sharing your experience, asking questions, or helping amplify the word about the registry, we invite you to be part of this discussion and help shape the future of metastatic breast cancer research.
Speaker
-
Mariya Rozenblit, M.D.Dr. Mariya Rozenblit is an Assistant Professor of Medicine in the section of Medical Oncology and cares for patients with a clinical focus on breast cancer. She completed her Fellowship in Medical Oncology-Hematology at Yale, Residency in Internal Medicine at NYU, and received her medical degree from Icahn School of Medicine. She is involved in educating medical students, residents, and fellows at Yale. Outside of the clinic, her focus is translational research with an interest in biomarker driven trial development in breast cancer.
In 2020, she was the recipient of the ASCO Conquer Cancer Foundation Young Investigator Award for her project, “Using single nucleotide variants of high functional importance to predict the risk of developing breast cancer in young women with high risk family history.” This award is for promising investigators to encourage and promote quality research in clinical oncology. In 2022, she was the recipient of the Susan G. Komen Career Catalyst Research Grant for her project, “Curing de novo oligometastatic HER2+ breast cancer”. This grant is to foster promising breast cancer researchers by providing support for up to three years.
X: @MariyaRozenblit
